Senores Pharmaceuticals Share Price
1258.80-22.70 (-1.77%)
+76.14% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
LAURUSLABSNSE
CIPLANSE
DRREDDYNSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
SENORESNSE
Senores Pharmaceuticals Share Price
1258.80-22.70 (-1.77%)
+76.14% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 162% | 59% |
| - | - | 139% | 108% |
| - | - | - | 75% |
| 15% | 15% | 17% | 14% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
LAURUSLABS
CIPLA
DRREDDY
MANKIND
AUROPHARMA
LUPIN
SENORES
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,764 | ₹419620 Cr | 34.69 | 12.07 | 62.82 | ₹11479 Cr |
| 9,030 | ₹239714 Cr | 81.95 | 34.04 | 128.41 | ₹2568 Cr |
| 4,584.1 | ₹174741 Cr | 80.12 | 16.72 | 97.06 | ₹2163 Cr |
| 1,140.2 | ₹112119 Cr | 24.84 | 9.42 | 62.53 | ₹5040 Cr |
| 2,018.5 | ₹110008 Cr | 100.61 | 6.8 | 29.25 | ₹889 Cr |
| 1,328 | ₹106061 Cr | 31.47 | 9.77 | 57.87 | ₹3879 Cr |
| 1,218.8 | ₹101339 Cr | 31.45 | 5.32 | 63.99 | ₹4196 Cr |
| 2,347.6 | ₹96244 Cr | 47.12 | 13.75 | 71.08 | ₹1913 Cr |
| 1,677.9 | ₹95590 Cr | 25.75 | 17.95 | 96.84 | ₹3505 Cr |
| 1,980.9 | ₹89391 Cr | 16.17 | 30.95 | 154.35 | ₹5333 Cr |
| 1,258.8 | ₹5904 Cr | 46.72 | 6.67 | 35.08 | ₹115 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹180 Cr | ₹175 Cr | ₹175 Cr | ₹162 Cr | ₹133 Cr | ₹114 Cr | ₹103 Cr | ₹101 Cr | ₹80 Cr | ₹102 Cr | ₹79 Cr |
| ₹3 Cr | ₹18 Cr | ₹4 Cr | ₹5 Cr | ₹9 Cr | ₹12 Cr | ₹5 Cr | ₹2 Cr | ₹48 L | ₹2 Cr | ₹80 L |
| ₹183 Cr | ₹193 Cr | ₹178 Cr | ₹167 Cr | ₹141 Cr | ₹126 Cr | ₹108 Cr | ₹102 Cr | ₹81 Cr | ₹104 Cr | ₹80 Cr |
| ₹136 Cr | ₹137 Cr | ₹128 Cr | ₹120 Cr | ₹110 Cr | ₹100 Cr | ₹82 Cr | ₹81 Cr | ₹63 Cr | ₹84 Cr | ₹67 Cr |
| ₹57 Cr | ₹65 Cr | ₹58 Cr | ₹55 Cr | ₹38 Cr | ₹31 Cr | ₹31 Cr | ₹25 Cr | ₹22 Cr | ₹24 Cr | ₹16 Cr |
| ₹7 Cr | ₹8 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr |
| ₹39 Cr | ₹47 Cr | ₹45 Cr | ₹41 Cr | ₹26 Cr | ₹21 Cr | ₹20 Cr | ₹16 Cr | ₹13 Cr | ₹18 Cr | ₹10 Cr |
| ₹30 Cr | ₹37 Cr | ₹34 Cr | ₹30 Cr | ₹21 Cr | ₹18 Cr | ₹16 Cr | ₹13 Cr | ₹11 Cr | ₹14 Cr | ₹7 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| — | — | — | — | — |
| ₹46 Cr | ₹46 Cr | ₹31 Cr | ₹10 Cr | ₹9 Cr |
| ₹29 L | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹887 Cr | ₹740 Cr | ₹174 Cr | ₹36 Cr | ₹28 Cr |
| ₹887 Cr | ₹740 Cr | ₹174 Cr | ₹36 Cr | ₹28 Cr |
| ₹934 Cr | ₹786 Cr | ₹204 Cr | ₹45 Cr | ₹37 Cr |
| ₹31 Cr | ₹26 Cr | ₹27 Cr | ₹0 | ₹0 |
| ₹111 Cr | ₹81 Cr | ₹28 Cr | ₹0 | ₹20,000 |
| ₹83 Cr | ₹82 Cr | ₹106 Cr | ₹30 Cr | ₹12 Cr |
| ₹59 L | -₹19 Cr | -₹15 Cr | ₹2 Cr | -₹45 L |
| ₹13 Cr | ₹8 Cr | ₹8 Cr | ₹2 Cr | ₹41 L |
| ₹7 Cr | ₹3 Cr | ₹1 Cr | ₹26 L | ₹5 L |
| ₹215 Cr | ₹155 Cr | ₹128 Cr | ₹34 Cr | ₹12 Cr |
| — | — | — | — | — |
| ₹235 Cr | ₹67 Cr | ₹113 Cr | ₹14 Cr | ₹7 Cr |
| ₹137 Cr | ₹127 Cr | ₹94 Cr | ₹28 Cr | ₹62 L |
| ₹29 Cr | ₹31 Cr | ₹32 Cr | ₹8 Cr | ₹2 Cr |
| ₹23 Cr | ₹16 Cr | ₹8 Cr | ₹2 Cr | ₹14 L |
| ₹424 Cr | ₹241 Cr | ₹248 Cr | ₹52 Cr | ₹10 Cr |
| ₹1604 Cr | ₹1208 Cr | ₹607 Cr | ₹131 Cr | ₹59 Cr |
| ₹24 Cr | ₹21 Cr | ₹23 Cr | ₹8 Cr | ₹0 |
| ₹327 Cr | ₹305 Cr | ₹248 Cr | ₹61 Cr | ₹14 Cr |
| — | — | — | — | — |
| ₹561 Cr | ₹331 Cr | ₹249 Cr | ₹30 Cr | ₹8 Cr |
| ₹62 Cr | ₹30 Cr | ₹13 Cr | ₹3 Cr | ₹1 Cr |
| ₹499 Cr | ₹301 Cr | ₹235 Cr | ₹27 Cr | ₹7 Cr |
| ₹17 Cr | ₹44 Cr | ₹18 Cr | ₹8 Cr | ₹35 L |
| ₹4 Cr | ₹1 L | ₹1 L | ₹16 Cr | ₹15 Cr |
| ₹4 Cr | ₹1 L | ₹1 L | ₹16 Cr | ₹15 Cr |
| ₹7 Cr | ₹9 Cr | ₹4 Cr | ₹1 Cr | ₹1 Cr |
| ₹8 Cr | ₹4 Cr | ₹19 Cr | ₹40 L | ₹14 L |
| ₹791 Cr | ₹486 Cr | ₹356 Cr | ₹80 Cr | ₹32 Cr |
| — | — | — | — | — |
| ₹89 Cr | ₹57 Cr | ₹37 Cr | ₹3 Cr | ₹3 Cr |
| ₹325 Cr | ₹124 Cr | ₹112 Cr | ₹22 Cr | ₹20 Cr |
| ₹160 Cr | ₹386 Cr | ₹13 Cr | ₹10 L | ₹3 Cr |
| ₹16 Cr | ₹7 Cr | ₹3 Cr | ₹1 Cr | ₹1 L |
| ₹223 Cr | ₹149 Cr | ₹85 Cr | ₹25 Cr | ₹1 Cr |
| ₹812 Cr | ₹722 Cr | ₹251 Cr | ₹51 Cr | ₹27 Cr |
| ₹388 Cr | ₹482 Cr | ₹3 Cr | -₹55 L | ₹17 Cr |
| ₹1604 Cr | ₹1208 Cr | ₹607 Cr | ₹131 Cr | ₹59 Cr |
| ₹203 | ₹171 | ₹67 | ₹46 | ₹42 |
| ₹203 | ₹171 | ₹67 | ₹46 | ₹42 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| ₹159 Cr | ₹71 Cr | ₹25 Cr | ₹12 Cr | ₹1 Cr |
| ₹58 Cr | ₹27 Cr | ₹18 Cr | ₹3 Cr | ₹1 Cr |
| -₹142 Cr | -₹134 Cr | -₹66 Cr | -₹15 Cr | -₹13 Cr |
| ₹75 Cr | -₹37 Cr | -₹23 Cr | ₹37 L | -₹10 Cr |
| ₹62 Cr | -₹46 Cr | -₹26 Cr | -₹1 Cr | -₹10 Cr |
| -₹121 Cr | -₹429 Cr | -₹54 Cr | -₹48 Cr | -₹24 Cr |
| -₹1 Cr | ₹573 Cr | ₹87 Cr | ₹46 Cr | ₹36 Cr |
| -₹60 Cr | ₹98 Cr | ₹7 Cr | -₹3 Cr | ₹2 Cr |
| ₹105 Cr | ₹8 Cr | ₹10 L | ₹3 Cr | ₹2 Cr |
| ₹1 L | ₹0 | ₹50 L | ₹0 | ₹0 |
| ₹46 Cr | ₹105 Cr | ₹8 Cr | ₹10 L | ₹3 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found
Senores Pharmaceuticals Share Price
1258.80-22.70 (-1.77%)
+76.14% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 3
Bearish signals: 6 out of 9 oscillators
RSI
32.83Sell
STOCH %K
2.65Buy
MACD Level(12,26)
-35.17Sell
Ultimate Oscillator
32.61Sell
Aroon Oscillator
-72.00Sell
BOP
-0.51Sell
CCI
-186.66Buy
Williams %R
-97.35Buy
Momentum
-85.50Sell
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 2
Bearish signals: 7 out of 9 moving averages
EMA 9
1316.30Sell
SMA 9
1325.00Sell
EMA 21
1353.16Sell
SMA 21
1355.04Sell
EMA 50
1373.40Sell
SMA 50
1419.12Sell
EMA 200
1151.27Buy
SMA 200
1093.65Buy
WMA 20
1336.28Sell
Pivot
Pivot
Classic
Resistance 5
1509.80
Resistance 4
1455.50
Resistance 3
1401.20
Resistance 2
1346.90
Resistance 1
1314.20
Pivot
1292.60
Support 1
1259.90
Support 2
1238.30
Support 3
1184.00
Support 4
1129.70
Support 5
1075.40
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Senores Pharmaceuticals Share Price
1258.80-22.70 (-1.77%)
+76.14% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| 45.82% | 45.82% | 45.80% | 45.80% | 45.78% | 45.77% |
| 6.62% | 3.64% | 3.35% | 4.28% | 3.66% | 4.17% |
| 3.21% | 4.55% | 4.44% | 5.08% | 6.51% | 6.43% |
| 6.56% | 5.07% | 4.88% | 3.54% | 3.00% | 3.23% |
| 37.79% | 40.92% | 41.53% | 41.30% | 41.05% | 40.40% |
Bulk & block deals
Name
Yashkumar Shantilal Sanghvi
Ravi Pawankumar Sanghvi
Astorne Capital Vcc Arven
Hrti Private Limited
Graviton Research Capital Llp
Graviton Research Capital Llp
Hrti Private Limited
Graviton Research Capital Llp
Qe Securities Llp
Qe Securities Llp
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 24 Dec 2025 | Sell | 21.88 Cr | ₹792 | 2.76 L | Bulk | 0.599888 | BSE |
| 24 Dec 2025 | Sell | 23.17 Cr | ₹792.19 | 2.92 L | Bulk | 0.63513 | BSE |
| 24 Dec 2025 | Sell | 39.61 Cr | ₹792.12 | 5 L | Bulk | 1.085691 | NSE |
| 29 Jul 2025 | Sell | 16.35 Cr | ₹688.87 | 2.37 L | Bulk | 0.515315 | NSE |
| 29 Jul 2025 | Sell | 21.81 Cr | ₹689.98 | 3.16 L | Bulk | 0.686355 | NSE |
| 29 Jul 2025 | Purchase | 21.79 Cr | ₹689.33 | 3.16 L | Bulk | 0.686355 | NSE |
| 29 Jul 2025 | Purchase | 18.49 Cr | ₹686.66 | 2.69 L | Bulk | 0.584675 | NSE |
| 24 Jul 2025 | Purchase | 43.79 Cr | ₹684.96 | 6.39 L | Bulk | 1.388133 | NSE |
| 24 Jul 2025 | Purchase | 16.77 Cr | ₹686.01 | 2.44 L | Bulk | 0.530677 | NSE |
| 24 Jul 2025 | Sell | 16.96 Cr | ₹684.18 | 2.48 L | Bulk | 0.538292 | NSE |
Insider trading & SAST
Client name
Ashokkumar Vijaysinh Barot
Dhananjay Barot
Dhananjay Ashokkumar Barot
Ashokkumar Vijaysinh Barot
Swapnil Jatin Shah & Others
Renosen Pharmaceuticals Private Limited
Sangeeta Mukur Barot
Swapnil Jatin Shah
Viraj Ashokkumar Barot
Ashokbhai Vijaysinh Barot
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 04 Sep 2026 | Promoter | Acquisition | 0.06 | 7.55 | 0 | — | 30 K | 10 Aug 2026 | Off Market / Inter se transfer | 34,74,869 | SAST | 29(2) | — |
| 04 Sep 2026 | Promoter | Disposal | 0.06 | 0.62 | 0 | — | 30 K | 10 Aug 2026 | Off Market / Inter se transfer | 2,82,689 | SAST | 29(2) | — |
| 12 Aug 2026 | Promoter Group | Disposal | 0.065141 | 0.62 | 0 | — | 30 K | 10 Aug 2026 | Off Market | 2,82,689 | Insider Trading | — | Equity |
| 12 Aug 2026 | Promoter | Acquisition | 0.065141 | 7.55 | 0 | — | 30 K | 10 Aug 2026 | Off Market | 34,74,869 | Insider Trading | — | Equity |
| 25 May 2026 | Promoter | Acquisition | — | 45.82 | 0 | — | 11.70 L | 28 Mar 2026 | Allotment Of Warrants On Preferential Basis | 2,11,00,357 | SAST | 29(2) | — |
| 01 Apr 2026 | Promoter Group | Acquisition | 1.604652 | 63.16 | 60.01 Cr | ₹812 | 7.39 L | 28 Mar 2026 | Allotment | 7,39,000 | Insider Trading | — | Warrants |
| 01 Apr 2026 | Promoter Group | Acquisition | 0.13354 | 5.26 | 4.99 Cr | ₹812 | 61.50 K | 28 Mar 2026 | Allotment | 61,500 | Insider Trading | — | Warrants |
| 01 Apr 2026 | Promoter & Director | Acquisition | 0.427762 | 16.84 | 16 Cr | ₹812 | 1.97 L | 28 Mar 2026 | Allotment | 1,97,000 | Insider Trading | — | Warrants |
| 01 Apr 2026 | Promoter Group | Acquisition | 0.107483 | 4.23 | 4.02 Cr | ₹812 | 49.50 K | 28 Mar 2026 | Allotment | 49,500 | Insider Trading | — | Warrants |
| 01 Apr 2026 | Promoter & Director | Acquisition | 0.26708 | 10.51 | 9.99 Cr | ₹812 | 1.23 L | 28 Mar 2026 | Allotment | 1,23,000 | Insider Trading | — | Warrants |
Senores Pharmaceuticals Share Price
1258.80-22.70 (-1.77%)
+76.14% past 1 Year
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across
Corporate Actions
Date
Type
Details
Company details
Senores Pharmaceuticals Share Price
1258.80-22.70 (-1.77%)
+76.14% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Senores Pharmaceuticals Share Price
1258.80-22.70 (-1.77%)
+76.14% past 1 Year
News
Senores Pharma Board Approves Director Reappointments Pending Shareholder Approval
Equity
SENORES
Senores Pharmaceuticals subsidiary Apnar Pharma clears routine USFDA GMP inspection
Equity
SENORES
Senores Pharmaceuticals to expand operations into Mexico and Canada markets
Equity
SENORES
Senores Pharmaceuticals to host analyst and investor meet on August 25
Equity
SENORES
Senores Pharma announces FY27 capex plan to expand manufacturing capacity
Equity
SENORES
Senores Pharma guided revenue target of Rs 2,500–3,000 crores in 3–4 years
Equity
SENORES
Senores Pharma guides strong branded generics growth with profitability focus
Equity
SENORES
Senores Pharma guides FY27 emerging market EBITDA margin at 18-20%
Equity
SENORES
Senores Pharma issues FY27 guidance with strong revenue and PAT growth targets
Equity
SENORES
Senores Pharma Q1 EBITDA nearly doubles YoY with strong margin expansion
Equity
SENORES
Senores Pharma Q1 revenue rises sharply year-on-year to Rs 180 crores
Equity
SENORES
Senores Pharma reports higher Q1 net profit at Rs 30.70 crores
Equity
SENORES
Senores Pharmaceuticals to hold Q1FY27 earnings conference call on July 27
Equity
SENORES
Senores Pharmaceuticals to host analyst and investor meet on July 7, 10 AM
Equity
SENORES
Senores Pharmaceuticals informs about analyst meet
Equity
SENORES
Senores Pharmaceuticals informs about press release
Equity
SENORES
Senores Pharma issues strong FY27 guidance with robust revenue, profit growth outlook
Equity
SENORES
Senores Pharmaceutic - Quaterly Results
Equity
SENORES
Senores Pharmaceutic reports Profit after tax of 8.48 Crores, in the March 2026 quarter
Equity
SENORES
Senores Pharma Reports Strong Q4 EBITDA Growth and Margin Expansion YoY
Equity
SENORES